- Latest available (Revised)
- Point in Time (01/04/2013)
- Original (As made)
Point in time view as at 01/04/2013.
There are currently no known outstanding effects for the The Controlled Drugs (Supervision of Management and Use) Regulations 2013, Section 11.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
11.—(1) An accountable officer (CDAO) of a provider body or a group of provider bodies must—
(a)establish and operate, or ensure that the provider body or each member of the group of provider bodies establishes and operates, appropriate arrangements for securing the safe management and use of controlled drugs by the CDAO's provider body or group of provider bodies; and
(b)review as appropriate, or ensure that the provider body or each member of the group of provider bodies reviews as appropriate, those arrangements.
(2) A CDAO of a commissioning body or a group of commissioning bodies must ensure that any person or undertaking that provides the body or group with relevant services—
(a)establishes and operates appropriate arrangements for securing the safe management and use of controlled drugs; and
(b)reviews as appropriate those arrangements.
(3) The arrangements mentioned in paragraphs (1) and (2) must include—
(a)appropriate arrangements for compliance with the Misuse of Drugs Act 1971 M1 and subordinate legislation under that Act;
(b)the following systems (which may be part of a single overarching system)—
(i)systems for recording concerns (including complaints) relating to the safe management or use of controlled drugs, and
(ii)incident reporting systems for untoward incidents relating to the safe management or use of controlled drugs; and
(c)up to date standard operating procedures in relation to the management and use of controlled drugs, which cover (amongst other matters) best practice relating to—
(i)the prescribing, supply and administration of controlled drugs, and
(ii)clinical monitoring of patients who have been prescribed controlled drugs.
(4) A CDAO of a provider body or group of provider bodies must ensure that any person who—
(a)as regards that provider body or group of provider bodies is a relevant individual; and
(b)needs information on, or education or training in relation to, the standard operating procedures referred to in paragraph (3)(c),
receives, as appropriate, that information, education or training.
Marginal Citations
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: